All Stories

  1. ENHANCE: A community partnership charting the evolution of early life CF disease manifestations in a new era of management
  2. Variability in the management of portal hypertension across European countries: A survey‐study by ESPGHAN Portal Hypertension Special Interest Group
  3. Update on pediatric liver transplantation in Europe 2022: An ELITA‐ESPGHAN report
  4. Early postnatal hepatocyte transplantation in a child with molybdenum cofactor deficiency type B
  5. Investigation of an outbreak of novel hepatitis of unknown aetiology in children and adolescents, Ireland, 2021 to 2023
  6. Higher-Dose Infliximab Induction Achieves Better Maintenance Trough Levels in a National Pediatric IBD Cohort—A Retrospective Study
  7. Primary sclerosing cholangitis in children with inflammatory bowel disease: An ESPGHAN position paper from the Hepatology Committee and the IBD Porto group
  8. FISH–Flow Cytometry Reveals Microbiome-Wide Changes in Post-Translational Modification and Altered Microbial Abundance Among Children with Inflammatory Bowel Disease
  9. New guidelines for screening, evaluation and management of hepatobiliary disease in cystic fibrosis
  10. Reply: Development and validation of pFIB scores for exclusion of significant liver fibrosis in pediatric MASLD
  11. Reply: Can pFIB scores reliably exclude significant liver fibrosis in pediatric MASLD?
  12. MRI-serum–based score accurately identifies patients undergoing liver transplant without rejection avoiding the need for liver biopsy: A multisite European study
  13. Development and validation of pFIB scores for exclusion of significant liver fibrosis in pediatric MASLD
  14. Novel Staged Device Occlusion of Portosystemic Shunt With Atrial Flow Regulator in IVC Stent Platform
  15. Paediatric steatotic liver disease has unique characteristics: A multisociety statement endorsing the new nomenclature
  16. ESPGHAN recommendations on treatment of chronic hepatitis C virus infection in adolescents and children including those living in resource‐limited settings
  17. The natural history of cystic fibrosis liver disease a prospective cohort study
  18. Intraperitoneal transplant of Hepatocytes co-Encapsulated with mesenchymal stromal cells in modified alginate microbeads for the treatment of acute Liver failure in Pediatric patients (HELP)—An open-label, single-arm Simon’s two stage phase 1 study pro...
  19. Systemic Complications Secondary to Chronic Liver Disease
  20. Diagnosis of fatty liver in children should occur in parallel to investigation for other causes of liver disease
  21. Adeno-Associated Virus 2 and Human Adenovirus F41 in Wastewater during Outbreak of Severe Acute Hepatitis in Children, Ireland
  22. Fatty liver disease in children (MAFLD/PeFLD Type 2): unique classification considerations and challenges
  23. Advances in medical management of acute liver failure in children: promoting native liver survival
  24. Acute Hepatitis of Unknown Etiology Among Young Children
  25. The impact of liver disease on mortality in cystic fibrosis–A systematic review
  26. Nonalcoholic Fatty Liver Disease
  27. New Horizons in Paediatric Hepatology: A Glimpse of the Future
  28. Nonalcoholic Fatty Liver Disease
  29. Emerging clinical perspectives in cystic fibrosis liver disease
  30. Transient elastography lacks precision in children
  31. Current Practices on Diagnosis, Prevention and Treatment of Post-Transplant Lymphoproliferative Disorder in Pediatric Patients after Solid Organ Transplantation: Results of ERN TransplantChild Healthcare Working Group Survey
  32. NAFLD to MAFLD in adults but the saga continues in children: an opportunity to advocate change
  33. The impact of liver disease on mortality in cystic fibrosis - a systematic review protocol
  34. Clinical management of sickle cell liver disease in children and young adults
  35. Pediatric Focal Lesions in the Liver: A Clinical Perspective
  36. Repeatability of transient elastography in children
  37. Prognostication in Paediatric Acute Liver Failure
  38. Small for Gestational Age Infants: Reading Their Future
  39. Cross-cutting view of current challenges in paediatric solid organ and haematopoietic stem cell transplantation in Europe: the European Reference Network TransplantChild
  40. Alginate microencapsulated human hepatocytes for the treatment of acute liver failure in children
  41. Childhood and Adolescent Nonalcoholic Fatty Liver Disease: Is It Different from Adults?
  42. Improving engraftment of hepatocyte transplantation using alpha-1 antitrypsin as an immune modulator
  43. Understanding susceptibility and targeting treatment in non-alcoholic fatty liver disease in children; moving the fulcrum
  44. Methylcellulose as a scaffold in the culture of liver-organoids for the potential of treating acute liver failure
  45. Transient Elastography Measurements of Spleen Stiffness as a Predictor of Clinically Significant Varices in Children
  46. Immunosuppression Protocol in Liver Transplantation
  47. A New High Throughput Screening Platform for Cell Encapsulation in Alginate Hydrogel Shows Improved Hepatocyte Functions by Mesenchymal Stromal Cells Co-encapsulation
  48. Correction to: Proteomic identification and characterization of hepatic glyoxalase 1 dysregulation in non-alcoholic fatty liver disease
  49. Paediatric fatty liver disease (PeFLD): All is not NAFLD – Pathophysiological insights and approach to management
  50. Vitamin D status and associated genetic polymorphisms in a cohort of UK children with non-alcoholic fatty liver disease
  51. Health Related Quality of Life and Neurocognitive Outcomes in the First Year after Pediatric Acute Liver Failure
  52. Hepatocyte transplantation and advancements in alternative cell sources for liver-based regenerative medicine
  53. Cryopreserved neonatal hepatocytes may be a source for transplantation: Evaluation of functionality toward clinical use
  54. Proteomic identification and characterization of hepatic glyoxalase 1 dysregulation in non-alcoholic fatty liver disease
  55. Human hepatocyte transplantation for liver disease: current status and future perspectives
  56. Fifteen-minute consultation: liver disease in children
  57. Autoimmune Liver Disease in Children with Sickle Cell Disease
  58. Systematic Review
  59. Allograft steatosis in the midst of the epidemic of obesity: Are children in the honeymoon period?
  60. Interim assessment of liver damage in patients with sickle cell disease using new non-invasive techniques
  61. Instant Blood-Mediated Inflammatory Reaction in Hepatocyte Transplantation: Current Status and Future Perspectives
  62. AST-to-platelet ratio index in non-invasive assessment of long-term graft fibrosis following pediatric liver transplantation
  63. Biomarkers in Pediatric Liver Disease
  64. Assessment of Diet and Physical Activity in Paediatric Non-Alcoholic Fatty Liver Disease Patients: A United Kingdom Case Control Study
  65. Bile Acids As Biomarkers - Liver And Gut Cross Talk in NAFLD
  66. Nonalcoholic Fatty Liver Disease
  67. Coculture with Mesenchymal Stem Cells Results in Improved Viability and Function of Human Hepatocytes
  68. Scanning the Scars
  69. Hepatopathy of Mauriac syndrome: a retrospective review from a tertiary liver centre
  70. Noninvasive biomarkers in non-alcoholic fatty liver disease: Current status and a glimpse of the future
  71. Management of Cholestatic Pruritus in Paediatric Patients With Alagille Syndrome
  72. Chronic Acetaminophen Exposure in Pediatric Acute Liver Failure
  73. Transient Elastography Is a Useful Noninvasive Tool for the Evaluation of Fibrosis in Paediatric Chronic Liver Disease
  74. Analysis of adipokine concentrations in paediatric non-alcoholic fatty liver disease
  75. Serum protein N-glycosylation in paediatric non-alcoholic fatty liver disease
  76. Serum Levels of CK18 M30 and Leptin Are Useful Predictors of Steatohepatitis and Fibrosis in Paediatric NAFLD
  77. Predictive Value of Bile Duct Dimensions Measured by Ultrasound in Neonates Presenting With Cholestasis
  78. Fatty liver disease in children: eat now pay later
  79. Human hepatocyte transplantation: state of the art
  80. Crigler–Najjar syndrome: therapeutic options and consequences of mutations in the UGT1A1 complex
  81. The Incidence of Cyclic Vomiting Syndrome in Children: Population-Based Study.
  82. Outcome for children with cyclical vomiting syndrome
  83. A confused child: Answer
  84. A confused child: Question